The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Abstract
Importance: US law requires testing of new drugs before approval to ensure that they provide a well-defined benefit that is commensurate with their risks. A major challenge for the US Food and Drug Administration (FDA) is to achieve an appropriate balance between rigorous testing and the need for timely approval of drugs that have benefits that outweigh their risks. Objective: To describe the evolution of laws and standards affecting drug testing, the use of new approval programs and standards, expansions of the role and authority of the FDA, and changes in the number of drugs approved from the 1980s to 2018. Evidence: Sources of evidence included principal federal laws and FDA regulations (1962-2018) and FDA databases of approved new drugs (1984-2018), generic drugs (1970-2018), biologics (1984-2018), and vaccines (1998-2018); special development and approval programs (Orphan drug [1984-2018], Fast-Track [1988-2018], Priority Review and its predecessors [1984-2018], Accelerated Approval [1992-2018], and Breakthrough Therapy [2012-2018]); expanded access (2010-2017) and Risk Evaluation and Mitigation Strategies (2008-2018); and user fees paid to the FDA by industry (1993-2018). Findings: From 1983 to 2018, legislation and regulatory initiatives have substantially changed drug approval at the FDA. The mean annual number of new drug approvals, including biologics, was 34 from 1990-1999, 25 from 2000-2009, and 41 from 2010-2018. New biologic product approvals increased from a median of 2.5 from 1990-1999, to 5 from 2000-2013, to 12 from 2014-2018. The median annual number of generic drugs approved was 136 from 1970 to the enactment of the Hatch-Waxman Act in 1984; 284 from 1985 to the enactment of the Generic Drug User Fee Act in 2012; and 588 from 2013-2018. Prescription drug user fee funding expanded from new drugs and biologics in 1992 to generic and biosimilar drugs in 2012. The amount of Prescription Drug User Fee Act fees collected from industry increased from an annual mean of $66 million in 1993-1997 to $820 million in 2013-2017, and in 2018, user fees accounted for approximately 80% of the salaries of review personnel responsible for the approval of new drugs. The proportion of drugs approved with an Orphan Drug Act designation increased from 18% (55/304) in 1984-1995, to 22% (82/379) in 1996-2007, to 41% (154/380) in 2008-2018. Use of Accelerated Approval, Fast-Track, and Priority Review for new drugs has increased over time, with 81% (48/59) of new drugs benefiting from at least 1 such expedited program in 2018. The proportion of new approvals supported by at least 2 pivotal trials decreased from 80.6% in 1995-1997 to 52.8% in 2015-2017, based on 124 and 106 approvals, respectively, while the median number of patients studied did not change significantly (774 vs 816). FDA drug review times declined from more than 3 years in 1983 to less than 1 year in 2017, but total time from the authorization of clinical testing to approval has remained at approximately 8 years over that period. Conclusions and Relevance: Over the last 4 decades, the approval and regulation processes for pharmaceutical agents have evolved and increased in complexity as special programs have been added and as the use of surrogate measures has been encouraged. The FDA funding needed to implement and manage these programs has been addressed by expanding industry-paid user fees. The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
Self-citationClinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2014) · JAMA · doi:10.1001/jama.2013.282034 · Cited by 407
Beaver, J. A., Howie, L. J., Pelosof, L., Kim, T., Liu, J., Goldberg, K. B., Sridhara, R., Blumenthal, G. M., Farrell, A. T., Keegan, P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5618 · Cited by 298
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
Kesselheim, A. S. (2011) · JAMA · doi:10.1001/jama.2011.769 · Cited by 230
Self-citationThe FDA Sentinel Initiative — An Evolving National Resource
Platt, R., Brown, J. S., Robb, M., McClellan, M., Ball, R., Nguyen, M. D., & Sherman, R. E. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1809643 · Cited by 216
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015) · BMJ · doi:10.1136/bmj.h4633 · Cited by 189
Self-citationRegulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing, N. S., Aminawung, J. A., Shah, N. D., Braunstein, J. B., Krumholz, H. M., & Ross, J. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmsa1200223 · Cited by 176
Cited by
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Rasool, R. U., Ahmad, H. F., Rafique, W., Qayyum, A., & Qadir, J. (2022) · Journal of Network and Computer Applications · doi:10.1016/j.jnca.2022.103332 · Cited by 177
Mishra, A., Aghaee, M., Tamer, I. M., & Budman, H. (2025) · Spectroscopy Journal · doi:10.3390/spectroscj3020012 · Cited by 19
Metadata
- Authors
- Darrow, J. J., Avorn, J., & Kesselheim, A. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-01-14
- Volume
- 323
- Issue
- 2
- Pages
- 164
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2998984898
- Cited by
- 377
- References
- 30
- FWCI
- 44.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval and Regulation of Pharmaceuticals, 1983-2018. https://app.cochat.ai/papers/10.1001/jama.2019.20288
- The paper
- Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020). FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA. https://doi.org/10.1001/jama.2019.20288
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.